MOESM2 of Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases

Description

Additional file 2. This file includes all the references screened in the systematic review and the reason for exclusion.

Date made available	22 Oct 2019
Publisher	figshare

DOI
10.6084/m9.figshare.10022105

1 Article

Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases
Sampayo-Cordero, M., Miguel-Huguet, B., Pardo-Mateos, A., Malfettone, A., Pérez-García, J., Llombart-Cussac, A., Cortés, J., Moltó-Abad, M., Muñoz-Delgado, C., Pérez-Quintana, M. & Pérez-López, J., 21 Oct 2019, In: Orphanet Journal of Rare Diseases. 14, 1, 230.
Research output: Contribution to journal › Article › Research › peer-review

Open Access
18 Citations (Scopus)

Cite this

Sampayo-Cordero, M. (Creator), Miguel-Huguet, B. (Contributor), Pardo-Mateos, A. (Creator), Malfettone, A. (Creator), Pérez Garcia, J. I. (Creator), Llombart-Cussac, A. (Creator), Cortés, J. (Creator), Moltó-Abad, M. (Creator), Muñoz-Delgado, C. (Creator), Pérez-Quintana, M. (Creator), Pérez-López, J. (Creator) (22 Oct 2019). MOESM2 of Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases. figshare. 10.6084/m9.figshare.10022105